

Test Description

EGFR mutation test is an *in vitro* diagnostic test for the qualitative detection of mutations in exons 18, 20, 21; deletions in exon 19 and insertions in exon 20 of *EGFR* oncogene.

Patient Demographic

Name: Hayder Sabur Sex: Male Date of Birth/Age: 44 Years Disease: NSCLC

PATIENT	REPORT DATE	BOOKING ID
Hayder Sabur	29- Apr 2019	011904290056

Clinician

Clinician Name: Dr Randeep Singh Medical Facility: Artemis Hospital Pathologist: Not Provided

Specimen

Site: Lung Sample Type: FFPE block C 2062/19 Date of Collection: 29-04-2019 Date of Booking: 29-04-2019

EGFR Mutation Analysis

Result

Deletion Detected in Exon 19

GENOMIC FINDINGS

Deletion: Exon 19 (Del9/Del12/Del15/Del18/Del21/Del24)

INTERPRETATION

Deletion in exon 19 of *EGFR* gene is detected.

The genotype calls Exon 19 deletion cover mutation group consisting of Del9, Del12, Del15, Del18, Del21 and Del24. Mutation can be detected for any of these genotype calls, no additional information on the mutant type is provided for this qualitative assay,

For valid batch test results specific controls are being run with every batch.

METHODOLOGY

The Biocartis Idylla[™] EGFR Mutation Test is an *in vitro* diagnostic test intended for the qualitative detection of 51 alterations in exon 18 (G719A/C/S), exon 21 (L858R, L861Q), exon 20 (T790M, S768I) mutations, exon 19 deletions and exon 20 insertions in the *EGFR* oncogene. The Test uses formalin-fixed, paraffin-embedded (FFPE) tissue sections from human non-small cell lung cancer (NSCLC) tissue. A conserved fragment in the transmembrane region of the *EGFR* gene is amplified simultaneously. This PCR reaction, EGFR total, serves as a sample processing control (SPC) that checks for adequate execution of the complete process from sample to result, and is present in each of the five multiplexes. In addition, the EGFR control reaction is a measure for the amount of amplifiable DNA in the sample and is used in the analysis of the mutation status of the sample. This test is carried out on Idylla platform using the EGFR/1.0 Cartridge based kit which is CE IVD approved.

The Idylla^M EGFR Mutation Test is able to detect allelic frequencies at: $\leq 5\%$ for mutations in exons 19, 20 and 21 of the *EGFR* oncogene; and $\leq 10\%$ for mutations in exon 18 of the *EGFR* oncogene

REFERENCES

Montpreville et al. Path Res &Prac (2017) 213:793-98
Lambros et al. J clin Path (2017) 0:1-6

April 29, 2019

Dr Gulshan Yadav, MD, Consultant Pathology

Date